GWP42003-P
Phase 3TerminatedDevelopment Stage
Seizure in Participants With Tuberous Sclerosis Complex
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
May 19, 2021 → Jan 28, 2025
About GWP42003-P
GWP42003-P is a phase 3 stage product being developed by Jazz Pharmaceuticals for Seizure in Participants With Tuberous Sclerosis Complex. The current trial status is terminated. This product is registered under clinical trial identifier NCT04485104. Target conditions include Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome.
Hype Score Breakdown
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04485104 | Phase 3 | Terminated |
| NCT04133480 | Approved | Withdrawn |
| NCT04252586 | Phase 3 | Terminated |
| NCT02954887 | Phase 3 | Completed |
| NCT02953548 | Phase 3 | Completed |
| NCT02607904 | Phase 2 | Completed |
| NCT02544750 | Phase 3 | Completed |
Competing Products
20 competing products in Seizure in Participants With Tuberous Sclerosis Complex
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2007 | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| perampanel + perampanel + perampanel + Placebo | Eisai | Phase 3 | 77 |
| perampanel | Eisai | Phase 2 | 52 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 77 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 77 |
| Perampanel + Placebo | Eisai | Phase 3 | 77 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 77 |
| Adjunctive Zonisamide + Replacement with Zonisamide | Eisai | Approved | 85 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Eslicarbazepine Acetate tablets | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Approved | 85 |